Afternoon Symposium - LPG, SMRU, and SRBT - Assisted Reproduction for the HIV-discordant Couple

Date:October 22, 2012

Time:4:15 pm - 6:15 pm

Location:Room 6E - San Diego Convention Center

Presenters

Erma Z. Drobnis, Ph.D. (Chair), University of Missouri Women’s Health Center

Sangita K. Jindal, Ph.D., Montefiore Institute

Ann Kiessling, Ph.D., Bedford Research Foundation

John Y. Phelps, J.D., Ph.D., University of Texas Health Branch

Assisted Reproduction for the HIV-discordant Couple 

Needs Assessment and Description 
Due to improved treatments for human immunodeficiency virus (HIV) infection, this disease is now viewed as a chronic illness and many infected individuals wish to have children. Although treatment of HIV-discordant couples, in which the man is HIV-positive and the woman is not, is common in other countries, with more than 4000 cycles of in vitro fertilization (IVF) or intrauterine insemination (IUI) reported in the literature, practitioners in the United States have been reluctant to treat these couples. This live course for physicians, clinicians and reproductive scientists will review the legal, scientific and technical aspects of current treatments available for HIV-discordant couples

Learning Objectives
At the conclusion of this session, participants should be able to: 

  1. Describe why HIV-discordant couples require assisted reproduction. 
  2. Cite the risk of HIV transmission in HIV-discordant couples. 
  3. Identify government regulations regarding treatment of these patients. 
  4. Review methods of treating HIV-discordant couples including identification of measures to protect patients and clinic personnel when treating HIV-positive men in a fertility clinic.

ACGME Competency
Patient Care

TEST QUESTION:
An HIV-discordant couple comes to your clinic for treatment. They are married and use condoms regularly. They have been counseled to consider donor insemination, adoption, or remaining childless, and they remain committed to having a genetically-related child. After the initial workup, she is judged to be a good candidate for intrauterine insemination (IUI). All tests for infectious diseases are negative for both partners. His semen analysis results are shown: 

  Patient Result   Normal Reference
Volume (mL) 2.5 ≥ 1.4
Sperm concentration (million/mL) 20 ≥ 15
Total Sperm (million) 50 ≥ 39
Progressive Motility (%) 25% ≥ 32%
Normal Morphology (%) 5% ≥ 4%
Leucocyte concentration (million/mL)   1.2 < 1.0

He is under the treatment of an infectious disease specialist and his viral load and CD4 counts were stable for more than a year until 4 months ago when he discontinued his Highly Active Antiretroviral Therapy (HAART). After participating in this session, in my practice I will tell the patient the following about re-starting his HAART treatment: 

  1. He should wait to start taking HAART because it is known to decrease sperm motility and his sperm motility is already low. 
  2. He should avoid HAART because this treatment is known to cause birth defects in the children of treated fathers. 
  3. He should re-start his HAART because it increases CD4 count, which is associated with improved semen quality. 
  4. He should follow the advice of his infectious disease specialist and re-start HAART if indicated for his disease. 
  5. He should re-start his HAART to decrease the viral load and infectivity of his semen. 
  6. Not applicable to my area of practice.

ASRM MEMBERSHIP

View Details
Learn More | Join | Renew
Back to Top